HER2-negative Breast Cancer trials recruiting in Texas

All HER2-negative Breast Cancer trials nationally

Cities in Texas

Recruiting trials in Texas

• A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
  NCT06568692 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, San Antonio
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, San Antonio
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
  NCT05660083 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
  NCT06756932 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, Irving, San Antonio
• CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
  NCT05029999 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Texas: Dallas, San Antonio
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
  NCT05305924 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  NCT01042379 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, Houston, Temple
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  NCT07524322 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Texas: Austin, Bedford, Dallas, Houston